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1 
 
Abstract—Hemofiltration (HF) is a group of blood purification 
therapies used to treat patients with kidney injury. HF works 
using a process called ultrafiltration (UF) that removes excess 
liquid accumulated in the patient’s body caused by lack of 
excretion. UF progress is monitored by the HF machine, but the 
state-of-the-art method is cumbersome and could be more 
accurate. In this work, a system composed by two optical sensors 
is proposed for real-time non-invasive estimation of 
ultrafiltration rate. This new system is simple, rugged, low-cost 
and operates on sound theoretical foundations. The sensor system 
has been tested with two different experimental protocols and 
showed good correlation between its output and the reference 
value of the ultrafiltration rate (R2=0.97), as well as improved 
accuracy compared to the available commercial machine 
(≃12ml/h). This system also has the potential to simplify the 
architecture required by critical care blood purification 
machines to perform UF control. 
 
Index Terms — Biomedical Measurement, Blood, Blood 
Purification, Hemofiltration, Hemoglobin, Measurement, Optical 
Sensor, Ultrafiltration 
I. INTRODUCTION 
Renal replacement therapies (RRTs) have been developed to 
treat individuals affected by kidney failure, known as 
nephropathic patients. RRTs have the following targets: 
• Removal of excess fluid accumulated by the patient 
due to lack of kidney excretion. 
• Re-balancing concentration of specific substances in 
blood, for example electrolytes such as sodium. 
• Removal of the toxic by-products of metabolism, 
such as urea. 
 
Several types of therapies and machines have been developed. 
The main distinction of therapies is between those developed 
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to treat patients with acute kidney injury (AKI), who are 
expected to partially or fully regain kidney functionality, and 
those for patients with chronic kidney disease (CKD), who 
require periodic treatment for the rest of their lives or until 
kidney transplant. Therapies such as hemodialysis [1]–[3] and 
peritoneal dialysis [4] are the standard for CKD patients; while 
for AKI, slow, prolonged, one-time treatments are chosen to 
perform blood purification until kidney function is regained 
[5]–[7]. The effect of RRTs on the patient has been studied 
both clinically and with mathematical tools such as kinetic 
models, developed to describe the transfer of water and solutes 
across body compartments during RRTs [8]–[10].  
This work represents a technological improvement for AKI 
therapies where fluid removal is the main target – therapies 
also known as hemofiltration (HF). Fluid removal is 
performed by means of a physical principle called 
ultrafiltration (UF) [11]–[13]. Examples of specific 
hemofiltration therapies are slow continuous ultrafiltration 
(SCUF), continuous artero-venous (CAVH) and veno-venous 
hemofiltration (CVVH) [14]. Since fluid removal is the main 
target of these therapies, the process is monitored by 
technological means to ensure a stable ultrafiltration rate 
(UFR) and the achievement of the desired end-session target 
weight loss, usually by performing sensing and closed-loop 
control on UFR.  
This paper describes the development of a new type of 
sensor for hemofiltration RRTs. The sensor takes advantage of 
a differential optical measurement principle to measure UFR 
in a non-invasive manner, so that the system does not come 
into direct contact with blood. The new sensor has the 
potential of improving the accuracy of UFR estimation, and 
consequently its control, as well as simplifying the machine 
architecture. 
In section II, basic theoretical background on HF, UF and 
optical sensing is outlined. Section III describes the theoretical 
principles and technical aspects of the system, including a 
description of the experimental setup and protocols used for 
validation. Experimental results are reported in section IV. In 
section V, the results are analyzed, and current limitations of 
the system and probable future developments are discussed. 
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II. THEORETICAL BACKGROUND 
A. Hemofiltration and Ultrafiltration 
RRT therapies work by withdrawing blood from the patient, 
purifying it during extracorporeal circulation (EC), then re-
injecting it. Purification is performed by means of a filter, the 
dialyzer, placed along the EC circuit. In the case of 
hemofiltration, only fluid removal is performed at the filter, 
whereas re-injection of sterile fluid with different solutes is 
eventually performed further downstream. When the patient 
only needs treatment for fluid overload, no fluid re-injection is 
performed, corresponding to an isolated UF treatment [13]. 
Fig. 1 shows a simplified diagram of the hemofiltration 
process. Blood withdrawn from the patient flows along the 
extracorporeal path across the dialyzer by means of two roller 
pumps, while a third pump on the other side of the filter 
applies a negative pressure gradient across the dialyzer 
membrane, withdrawing water and small solutes but no large 
molecules or red blood cells. This process is called 
ultrafiltration. Waste liquid is collected in a bag, which is 
removed by the operator after the session. The diagram in 
Fig.1 is conceptual; a real HF set-up would also include 
additional pumps along the circuit for a range of purposes 
such as the injection of the anticoagulant (e.g. heparin) or 
replacement fluid (pre/post-dilution pumps).  
The ultrafiltration rate (UFR) is typically set either through 
the roller pump encoder and rounds-per-minute (rpm) settings, 
or by monitoring differential pressure across the 
hemodialyzer’s membrane and regulating the pump 
accordingly. The specific implementation is machine-
dependent. A secondary check is performed by an integrated 
electronic scale, which weighs the collected waste liquid in 
order to assess treatment progression, detect possible issues 
and correct UFR if needed.  
However, this method has drawbacks. The electronic scale is 
very sensitive to perturbations to the hanging waste bag, 
which may affect readings; the operator must take extreme 
care not to touch the bag during the session. Also, the waste 
bag must be replaced multiple times during the session, and 
during these times the UF process must be temporarily 
stopped. Thus, the present system for UFR control is 
encumbering and stressful for the operator. Accuracy for this 
kind of method of UFR control is approximately in the tens of 
ml/h; for example, the machine used in this research has a 
documented accuracy of 30 ml/h [15]. 
B. Optical sensors in hemodialysis and hemofiltration 
This work reports a novel system for HF treatments based 
on the application of sensors typically used on HD machines 
for different purposes. In this subsection, a brief description of 
such sensors is given. 
Several sensors are embedded on HD machines for on-line 
monitoring of relevant parameters and for patient safety, with 
new designs being periodically reported in literature [16]–
[19]. Non-invasive sensors are particularly useful to avoid the 
expense of disposable material and probes [16], [18], [20], 
[21]. Optical sensors are mainly used for the purpose of 
relative blood volume (RBV) estimation [22], [23], but other 
uses have also been proposed [16], [17], [19], [24], [25]. 
Relative blood volume is defined as the relative variation in 
volume of the body’s blood compartment in comparison with 
that at the beginning of the session. It is determined by the 
time-dependent balance between the UFR and the refilling rate 
(RR), which is the rate at which the patient physiologically 
refills the circulatory system with liquid coming from the 
extravascular space [26] to avoid a drop in blood pressure. 
Equation (1) shows the mathematical formulation for RBV, 
where t0 is the time at which the HD session starts. 
 
𝑅𝐵𝑉(𝑡) =
𝑉𝐵(𝑡)
𝑉𝐵(𝑡0)
=  
𝑉𝐵(𝑡0)−∫ 𝑈𝐹𝑅(𝑡)−𝑅𝑅(𝑡)
𝑡
𝑡0
𝑉𝐵(𝑡0)
       (1) 
 
Knowledge of RBV is useful for the purpose of patient-based 
therapy customization:  in the past, biofeedback algorithms 
were developed to tune HD session parameters in real-time on 
the basis of physiological variables [27]–[31]. For example, 
UFR can be modulated in real-time on the basis of an RBV 
estimate to avoid hypotensive events [29]. However, the blood 
volume at the session start VB(t0) is not known and its 
measurement would be impractical and invasive. Thus, RBV 
is calculated starting from the blood hemoglobin 
concentration, as shown in Eqs. (2-3). In Eq. (3) it is assumed 
that hemoglobin mass does not change significantly during the 
session, only blood volume does. 
 
[𝐻𝑔𝑏](𝑡) =
𝑚𝐻𝑔𝑏
𝑉𝐵(𝑡)
                 (2) 
 
𝑅𝐵𝑉(𝑡) =
[𝐻𝑔𝑏](𝑡0)
[𝐻𝑔𝑏](𝑡)
=
𝑚𝐻𝑔𝑏
𝑉𝐵(𝑡0)
 ∙
𝑉𝐵(𝑡)
𝑚𝐻𝑔𝑏
=
𝑉𝐵(𝑡)
𝑉𝐵(𝑡0)
      (3) 
 
In this context, optical sensing is used for the estimation of 
hemoglobin concentration in blood. The typical architecture of 
an optical sensor for HD is shown in Fig. 2.  
In this setup, a light source and a detector are placed across 
 
 
Fig. 1.  Simplified diagram of the hemofiltration process.  
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3 
the blood flow circuit - the bloodline - and light is transmitted 
across the bloodstream, usually across a special optically 
transparent section of the bloodline - the cuvette. The light 
source is typically a light-emitting diode (LED) and the 
detector is usually a photodiode. Light is emitted with a 
central wavelength of ≃810nm. At this wavelength, 
hemoglobin has the same optical absorbance regardless of its 
oxygen content. The relationship between transmitted light 
power PTX, received power PRX and hemoglobin concentration 
[Hgb] is regulated by Lambert-Beer’s equation, reported in eq. 
(4). 
 
𝑃𝑅𝑋 = 𝑃𝑇𝑋 ∙ 𝑒
−𝛼∙[𝐻𝑔𝑏]∙𝑑              (4) 
 
In the above equation,  is the molar attenuation coefficient 
and d is the optical path length. Thus, by knowing PTX, d and 
α, [Hgb] can be measured by optical means and used in the 
determination of RBV(t) in real-time according to Eq. (3). The 
real-world implementation of this type of sensor also includes 
calibration coefficients for practical issues such as voltage 
offsets and gain error in the electronics. 
III. MATERIALS AND METHODS 
A. Measurement Principle 
The optical measurement described in Section II.B is 
usually performed on HD machines for treatment of CKD 
patients. In the new system, this type of measurement is 
performed on machines for HF treatments in two distinct 
positions along the EC blood path: before and after the 
hemodialyzer. The difference between the two sensor outputs 
is quantitatively related to the physical effect that occurs in the 
dialyzer, i.e. ultrafiltration. Thus, the setup acts as a non-
invasive ultrafiltration rate sensor.  
The outputs of the two sensors are formalized in Eqs. (5-6), 
where K is a positive coefficient taking into account both the 
geometrical coupling between light source and detector and 
the transimpedance gain of the photodiode reading circuitry. It 
is assumed that coefficient K, emitter intensity PTX, and 
optical path length d are all equal for the two sensors: slight 
differences due to fabrication, tolerance of components and 
setup preparation are considered negligible. Molar attenuation 
coefficient α is by definition also the same. 
 
𝑉1 = 𝐾 ∙ 𝑃𝑅𝑋,1 = 𝐾 ∙ 𝑃𝑇𝑋 ∙ 𝑒
−𝛼∙[𝐻𝑔𝑏]1∙𝑑        (5) 
𝑉2 = 𝐾 ∙ 𝑃𝑅𝑋,2 = 𝐾 ∙ 𝑃𝑇𝑋 ∙ 𝑒
−𝛼∙[𝐻𝑔𝑏]2∙𝑑        (6) 
 
However, concentrations [Hgb]1 and [Hgb]2 will be different: 
the hemoglobin mass, mHgb in Eq. (2), will be distributed in a 
smaller volume post-filter due to the removal of fluid across 
the filter’s membrane. Thus, [Hgb]2 will be slightly higher 
than [Hgb]1, and transmitted light will be decreased, reducing 
V2 compared to V1. Assuming [Hgb] variations during the 
sessions are small, equation for V2 can be linearized around 
[Hgb]1, leading to: 
 
𝑉2 =  𝑉1 ∙ 𝑒
−𝛼∙([𝐻𝑔𝑏]2−[𝐻𝑔𝑏]1)∙𝑑 ≃ 
≃ 𝑉1 ∙ ( 1 − 𝛼 ∙ 𝑑 ∙ ([𝐻𝑔𝑏]2 − [𝐻𝑔𝑏]1) )        (7) 
 
The assumption of small [Hgb] variations is acceptable as long 
as blood volume loss is limited, as expected during the 
session. The magnitude of blood volume loss that would 
invalidate this assumption would be associated with additional 
complications (i.e. hypotension, fainting), leading to the 
interruption of the session and thus making the sensor output 
irrelevant. 
 The difference between signals V1 and V2 then assumes the 
following form: 
 
𝑉𝐷𝑖𝑓𝑓 = 𝑉1 − 𝑉2 ≃ 𝑉1 ∙ (𝛼 ∙ 𝑑) ∙ ([𝐻𝑔𝑏]2 − [𝐻𝑔𝑏]1)   (8) 
 
Given that mHgb is assumed constant, [Hgb]1-[Hgb]2 will only 
be influenced by the effect of UFR on blood volume VB. In 
this report, we assume for simplicity that: 
 
([𝐻𝑔𝑏]2 − [𝐻𝑔𝑏]1) = 𝑐 ∙ 𝑈𝐹𝑅           (9) 
 
where c is a generic positive constant. Equation (9) is 
physically sound, as an increase in ultrafiltration rate will also 
increase the disparity of hemoglobin concentration across the 
filter by increasing [Hgb]2. Eqs. (8) and (9) can be combined 
and normalized in respect to V1, resulting in an index linearly 
related to UFR: 
 
𝐼𝑈𝐹𝑅 =
𝑉𝐷𝑖𝑓𝑓
𝑉1
=
𝑉1−𝑉2
𝑉1
≃ (𝛼 ∙ 𝑑 ∙ 𝑐) ∙ 𝑈𝐹𝑅 = 𝐾′ ∙ 𝑈𝐹𝑅   (10) 
 
In Eq. (10) above, K’ is a positive coefficient used to 
aggregate all constant parameters. It should be highlighted that 
measurement of V1 and V2 or that of V1 and VDiff are both 
theoretically equivalent for the computation of the equation, 
however, VDiff is a very small signal compared to V1 and V2, 
and its time-dependent evolution may not be detectable if this 
signal is computed as the difference of previously digitized V1 
and V2. Thus, in our measurement setup VDiff is sampled as an 
analogue voltage signal in a differential configuration between 
the V1 and V2 voltages, while V1 is sampled independently as 
a single-ended signal. Afterwards, IUFR can be calculated and 
the UFR determined from an empirically estimated value of 
K’. 
 
 
Fig. 2.  Simplified diagram of a typical optical blood volume sensor for 
hemodialysis. 
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4 
B. Measurement Setup 
Measurement setup is composed of four parts: 
 Two sensor modules placed on the bloodline, 
before and after the dialyzer 
 A through-hole circuit board 
 A microcontroller-based prototyping board 
Each of the sensor modules is composed of a light-emitting 
diode (LED) light source and a photodiode with an integrated 
transimpedance amplifier. The LED and the photodiode are 
placed on opposite sides of a custom 3D-printed plastic 
housing, allowing the fitting of an optical flow-through 
cuvette between the two components to measure transmitted 
light. The photodiode is soldered on a small printed circuit 
board (PCB) to allow proper placement of the component and 
provide easier access to its pins. LEDs with a central emission 
wavelength of 810nm are used (MTE1081C, Marktech 
Optoelectronics, Latham, New York, USA). An OPT101 
photodiode and transimpedance amplifier (Texas Instruments, 
Dallas, Texas, USA) is used to convert light transmitted across 
the bloodline directly to a voltage output signal. The 
photodiode is set to its default configuration to allow for 
maximum gain. One of the sensor modules is shown in Fig. 3. 
Given our measurement principle, the physical location of 
the sensor modules is extremely relevant. As explained in the 
previous subsection, sensor modules are placed immediately 
before and after the hemodialyzer on the EC circuit. This way, 
the only physical quantity able to modify the properties of 
blood is UFR. 
Sensor modules are connected to a circuit board designed to 
include a current regulator for the LEDs, low-pass filters for 
the voltage outputs of the photodiodes and an analogue-to-
digital converter (ADC) for the digitization of the signals. A 
CAT4104 constant current LED driver (ON Semiconductor, 
Phoenix, Arizona, USA) is used together with an external 
6.8KΩ resistor to drive the LEDs with a regulated 18 mA 
current. Voltage outputs from the OPT101 photodiodes were 
processed by simple first-order low-pass analogue filters with 
a 5.3Hz cut-off frequency prior to analogue-to-digital 
conversion. An ADS1115 (Texas Instruments, Dallas, Texas, 
USA) ADC was used to digitize the signals. This ADC was 
specifically chosen for its 16-bit resolution and its capability 
of switching between single-ended measurements and 
differential measurements on its physical channel using only 
software instructions. This feature was necessary in order to 
separately convert all the relevant analogue measurements 
(V1, V2 and Vdiff). 
An Arduino UNO microcontroller-based prototyping board 
(https://www.arduino.cc) was used for the purpose of data 
collection and transmission and to supply the PCB with 5V 
voltage. The internal ADC of the Arduino board was not used 
since it only has 12-bit resolution. The Arduino board was 
programmed to take consecutive measurements of each single 
sensor output, ground-referenced, as well as the differential 
voltage between the two voltage outputs. On the basis of 
preliminary measurements, the ADC voltage range was 
dynamically set to ±4.096V for the single-ended 
measurements and to ±0.512V for the differential 
measurement. The sampling frequency for each of the three 
signals was 16 Hz. Collected data was transmitted from the 
Arduino board to a PC using the serial protocol over USB 
cable (virtual COM port). A custom interface developed in 
LabView (National Instruments, Austin, Texas, USA) was 
used for data visualization and storage.  
A diagram of the complete system is shown in Fig. 4.  
 
 
 
Fig. 4.  Diagram of the measurement system. Two sensor modules are placed before and after the dialyzer. A PCB manages current supply to the sensor module 
and data sampling, together with an Arduino board. Data is sent to a PC and recorded using LabView. 
 
 
Fig. 3.  Optical sensor module.  
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C. Experimental protocols and data analysis 
A commercial machine for AKI treatment (Prisma, 
Gambro/Hospal, Medolla, Italy) was used to test the system. 
Its disposable line was cut to insert the optical flow-through 
cuvette chosen for our setup and afterwards re-sealed using 
cyclohexanone. The machine was set in slow continuous 
ultrafiltration (SCUF) mode. Blood flow rate was set to 100 
ml/min. Three liters of rabbit blood were placed in a container 
and kept from coagulating using sodium citrate at the 
appropriate concentration of 4% w/v at 1:9 dilution and two 
experiments were performed. Hematocrit was measured before 
and after each protocol using a capillary centrifuge 
(Ematomed, Angelo Franceschini Srl, Italy). 
During the first experiment, ultrafiltration rate (UFR) was 
changed manually using the machine’s touchscreen in a 
progressively increasing and then decreasing manner (Fig. 5, 
top left panel). Steps of 50 ml/h were applied to UFR, starting 
from 10 ml/h up to 210 ml/h and then back to 10 ml/h. Each 
UFR value was kept constant for 3 minutes for a total protocol 
duration of 27 minutes. This protocol aimed at investigating 
the relationship between UFR and the optical signals. The 
second experiment followed the general concept of the first 
one by increasing and decreasing UFR in steps. However, in 
this case each transition was interleaved with a return step to 
10 ml/h. UFR steps were taken by starting from 10 ml/h and 
going to 60, 150 and 210 ml/h and back (Fig. 5, top right 
panel). Steps were 3-minutes long, bringing the total duration 
of this experiment to 39 minutes. The aims of this protocol 
were to investigate the possible presence of a baseline drift in 
the system and to collect additional data for the estimation of 
the UFR/optical relationship. 
Signal processing and data analysis were performed using 
Matlab (Mathworks, Natick, Massachussets, USA).  
Signals V1 and VDiff were first pre-processed using a finite-
impulse response (FIR) filter of the 20th order with a cut-off 
frequency of 0.6 Hz, in order to remove the blood-mediated 
oscillating effect of the machine’s roller pump on the optical 
signal. After filtering the two signals, IUFR was calculated 
according to Eq. (9) as VDiff/V1.  
From the available data, time intervals were selected for 
analysis from each 3-minute step; while for each UFR step, a 
100-second time interval was selected. 
 Intervals had to be selected manually to account for: 
 mismatch between the timing of the protocol and the 
operator-performed change in UFR 
 the time delay necessary for the machine to speed up or 
slow down the pump responsible for ultrafiltration. 
For each interval, the mean IUFR was computed. Afterwards, 
linear regression between the average IUFR values and the 
corresponding UFR was performed. From the linear regression 
coefficients, the estimated value of UFR was computed and 
compared with the reference value. 
IV. RESULTS 
In protocol #1, hematocrit was measured before and after 
the experiments at 32%, indicating an overall change of less 
than 1%. In protocol #2, hematocrit was 32% before the 
experiment and 33% after, due to the higher total 
 
 
Fig. 5. Results from the experimental measurements. Left column panels show data for protocol #1, right column panels show data from protocol #2. Top panels 
show reference UFR values set on the machine’s user interface. Middle panels show measured values for V1 (black) and V2 (grey). Lower panels show the 
computed value of IUFR as black lines, whereas the subset of data used for linear regression is shown in grey.  
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6 
ultrafiltration involved in this protocol.  
Fig. 5 shows the experimental results for both protocols. 
The middle panels show the trend of signal V1 and V2 in 
response to the UFR values shown in the top panels. It is clear 
from these graphs that signal V2, measured post-filter, changes 
in response to a change in UFR. This is consistent with our 
model reported in Eq. (7), as UFR creates a mismatch in 
hemoglobin concentration across the filter that causes a 
difference between signals V1 and V2. A decreasing trend is 
also observable in both signals: in V1 it is almost linear, 
whereas in V2 is it superimposed to the step responses. The 
brief signal spike in V2 in protocol #2 (middle-right panel, 
grey line, time 28-30min) is due to an erroneous stop of the 
blood flow, quickly restarted.  
The drift present in V1 in both protocols can be explained 
by the effect of recirculation: after ultrafiltration at the 
dialyzer, concentrated blood flows back to the container, 
mixes with the original pool, and re-enters the filter. Thus, the 
average value of [Hgb]1 will slightly increase over time 
decreasing V1. This effect should also be noticeable in actual 
patients, although the presence of other body compartments 
would counteract strong volume reductions with refilling. 
The recorded tracks for V1 and V2 also show that, for the 
UFR range tested, VDiff is in the order of tens of milliVolts. 
Thus, the choice of measuring VDiff directly with a differential 
amplifier configuration is justified in order to record such a 
small signal with improved resolution. 
Lower panels of Fig. 5 show the computed value for IUFR. 
For both protocols, the trend of IUFR shows a remarkable 
similarity with the reference UFR track reported in the upper 
left and right panels, supporting the hypothesis that IUFR can be 
used to estimate UFR from the optical data.  
Moreover, whereas signals V1 and V2 showed a trend of 
slow decrease due to the recirculation of concentrated blood, 
IUFR shows negligible signs of this effect. This is confirmed 
by the fact that the IUFR value in response to the baseline UFR 
level of 10 ml/min does not drift significantly. In fact, IUFR is 
virtually only sensitive to the effect of UFR steps. 
IUFR computed using data from protocol #2 clearly shows 
the presence of a time-dependent first-order step response. A 
likely explanation is that this behaviour is more evident in 
protocol #2 because the change in UFR is larger between 
consecutive steps and the machine’s ultrafiltration mechanism 
requires more time to set UFR to the value requested by the 
operator.  
In Fig. 6, results from linear regression between the 
reference UFR value and our index IUFR are shown. The linear 
regression process returned an R2 value of 0.97. This high R2 
value confirms the validity of fitting the data with a linear 
model. Comparing the UFR values predicted by the regression 
model with the reference UFR values yielded a mean±std error 
of -7.7±9.9 ml/h and an rms error of 12.4 ml/h, equivalent to 
0.21 ml/min.  
V. DISCUSSION AND CONCLUSION 
A. Analysis of the Results 
The first quantitative result of this work is the very high 
correlation found between the reference value of UFR and the 
IUFR index. Linear correlation between the two variables was 
also expected from theory, as reported in Section III.A., and 
these results demonstrate the sound theoretical basis of this 
work. 
Another quantitative result is the low rms error yielded 
when predicting UFR by linear regression from IUFR, which is 
≃12ml/h. This result indicates that our system has an accuracy 
approximately double to that of the UFR setting reported in 
the machine’s manual (30 ml/h)[14]. However, it should be 
mentioned that the UFR setting on the machine is also our 
UFR reference value for the linear regression. Thus, since the 
machine is also our gold standard, it cannot be formally 
demonstrated that our system has better accuracy, only equal. 
Nonetheless, the results obtained with this proof-of-concept 
setup show that our sensor system could be a valid 
replacement for the current state-of-the-art UFR monitoring 
method, with comparable or even better accuracy.  
In addition to the highly accurate monitoring of UFR, our 
system shows potential for another application: by numerical 
integration of the estimated UFR value, the total UF volume 
removed could be estimated at any moment during the session. 
This capability would significantly simplify the machine as 
there would be no more need for an electronic scale, although 
waste outflow by a bag or tubing would still be necessary. 
However, this additional improvement is dependent on the 
task of removing the systematic part of the estimation error, in 
order to avoid long-term drifts in the value of the total 
estimated UF volume. This could be accomplished by periodic 
calibration of the sensors performed during short periods at 
zero or minimum, known UFR. 
The main strengths of this system are its cheapness, 
ruggedness and simplicity: whereas other optical flow 
measurement techniques like laser doppler or particle image 
velocimetry could be employed, they would require more 
complex, expensive and/or delicate setups. 
The robustness and compact size of our system also means 
it could be integrated into smaller blood purification systems 
currently being developed, such as portable artificial kidneys, 
 
Fig. 6.  Linear regression between reference UFR values and index IUFR, 
shown by the black line. Data points from experimental measurements are 
represented by black dots.  
1558-1748 (c) 2018 IEEE. Personal use is permitted, but republication/redistribution requires IEEE permission. See http://www.ieee.org/publications_standards/publications/rights/index.html for more information.
This article has been accepted for publication in a future issue of this journal, but has not been fully edited. Content may change prior to final publication. Citation information: DOI 10.1109/JSEN.2018.2865493, IEEE Sensors
Journal
> REPLACE THIS LINE WITH YOUR PAPER IDENTIFICATION NUMBER (DOUBLE-CLICK HERE TO EDIT) < 
 
7 
an area attracting growing interest. 
Ultrafiltration can also be used to treat some types of heart 
failure[11], [13]; another possible target application for this 
system in addition to AKI/RRTs. 
B. Limitations and Future Developments 
The sensor system has some limitations, which at present 
have negligible effect on the quality of the work but will be 
nonetheless addressed in future stages of the project: 
1. The main limitation of this work is that additional factors 
that may influence the optical measurements, and thus 
the relationship with UFR, have not yet been investigated 
in these studies. Examples of such factors are the level of 
blood dilution and the blood flow rate, which have been 
kept constant in our experiment. 
2. Data for correlation was chosen manually during pre-
processing. This was necessary as a commercial HD 
machine was used and the true instantaneous value of 
UFR was unknown to us. As shown in Fig. 5, data was 
only excluded from the transients when the set UFR 
value was not guaranteed and all steady-state data was 
kept.  
3. Only one experimental session, comprised of two 
experiments with different protocols, has been 
conducted. However, results show that the collected data 
is in accordance with the theoretical part of the work, and 
a strong linear correlation exists between the measured 
quantity, the IUFR index, and the ultrafiltration rate UFR. 
Overall, the quality of collected data is very high for one 
experimental session. 
4. LED sources in the setup were powered with constant 
current without any modulation scheme. However, care 
was taken to shield sensor housings from environmental 
light. Moreover, no slow long-term drift in light source 
power may have influenced our results since data was 
collected using a dynamic protocol with UFR steps. 
In future developments of this work, additional 
experimental sessions will be conducted, both to enlarge the 
dataset collected with the existing protocols, and to investigate 
the effect of the abovementioned additional factors. The new 
measurement circuit will also include Pulse-Width Modulation 
(PWM) for the light sources. If available, a setup with UFR 
value known in real time will be used.  
C. Conclusion 
In conclusion, a simple yet highly performing non-invasive 
sensor system has been developed to estimate ultrafiltration 
rate in ultrafiltration-based blood purification therapies such as 
HF and SCUF. The system is simple, rugged, low-cost and 
operates on sound theoretical foundations. Compared to state-
of-the-art systems, it has improved accuracy and the potential 
to drastically simplify the architecture needed in blood 
purification machines to perform UF control. 
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